- Advertise
- About OncLive
- Editorial Board
- CancerNetwork.com
- CGTlive.com
- CureToday.com
- OncNursingNews.com
- TargetedOnc.com
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
AZD1390 Demonstrates Initial Safety, May Enhance Radiotherapy Efficacy in Glioblastoma
April 9th 2024, 7:05pm
Early safety and efficacy data seen with AZD1390 in a phase 1 study indicate it's potential utility as a radiosensitizing treatment in glioblastoma.
Mirvetuximab Soravtansine Plus Pembrolizumab Makes a Splash in pMMR/MSS FRalpha+ Endometrial Cancer
April 9th 2024, 2:57pm
Mirvetuximab soravtansine plus pembrolizumab displays efficacy in recurrent or persistent, FRalpha-positive, pMMR/MSS serous endometrial cancer.
Dr Srour on the Safety and Efficacy of the Allogeneic CAR T-Cell Therapy CTX130 in Advanced ccRCC
April 9th 2024, 12:58am
Samer A. Srour, MB ChB, MS, discusses efficacy and safety data for the allogeneic CAR T-cell therapy CTX130 in advanced clear cell renal cell carcinoma.
Olaparib With Chemotherapy Does Not Elicit Improved Outcomes vs Chemotherapy Alone in BRCA Wild-Type TNBC
April 8th 2024, 9:53pm
Olaparib on a gap schedule with chemotherapy does not improve responses vs chemotherapy alone in the neoadjuvant setting for patients with BRCA wild-type TNBC.
Dr Porter on Mirvetuximab Soravtansine Plus Pembrolizumab in FRα+ pMMR/MSS Endometrial Cancer
April 8th 2024, 9:10pm
Rebecca L. Porter, MD, PhD, discusses the evaluation of mirvetuximab soravtansine plus pembrolizumab in FRα-positive, pMMR/MSS endometrial cancer.
Copanlisib Plus Nivolumab Demonstrates Activity in Microsatellite Stable Colorectal Cancer
April 8th 2024, 7:40pm
Copanlisib plus nivolumab was active and met the primary end point of a phase 1/2 study in a cohort of patients with MSS CRC.
Exosome-Based Assay Shows Diagnostic Sensitivity, Specificity in Pancreatic Cancer
April 8th 2024, 7:31pm
A microRNA assay combined with CA19-9 displayed diagnostic accuracy in the early detection of pancreatic cancer.
Saruparib Generates Early Efficacy and Safety Signals in HRR-Mutant Advanced Breast Cancer
April 8th 2024, 6:48pm
Saruparib's favorable activity and safety may allow patients with advanced solid tumors to stay on treatment longer vs other approved PARP inhibitors.
Adagrasib/Cetuximab Combo Has Activity in KRAS G12C+ Locally Advanced or mCRC
April 8th 2024, 6:43pm
Adagrasib plus cetuximab elicited a 34% objective response rate in patients with previously treated KRAS G12C-mutant advanced colorectal cancer.
Atezolizumab Fails to Improve Survival Outcomes After Definitive Local Therapy in High-Risk HNSCC
April 8th 2024, 6:00pm
Administration of atezolizumab after definitive local therapy did not improve EFS or OS in patients with head and neck squamous cell carcinoma.
Linvoseltamab Elicits Deep Responses in Late-Stage R/R Multiple Myeloma
April 8th 2024, 2:37pm
Linvoseltamab elicited responses with acceptable safety in patients with relapsed/refractory multiple myeloma, including difficult-to-treat subsets
CTX130 Provides Disease Control and Manageable Safety in Advanced ccRCC
April 8th 2024, 2:15pm
The anti-CD70 CAR T-cell therapy CTX130 showed activity and manageable toxicities in advanced renal cell carcinoma.
Dr Wong on Atezolizumab After Definitive Local Therapy in High-Risk HNSCC
April 8th 2024, 3:20am
Deborah J. Wong, MD, PhD, discusses the evaluation of atezolizumab vs placebo after definitive local therapy in high-risk, locally advanced HNSCC.
Dr Migden on RP1 in Advanced Cutaneous Malignancies After Solid Organ Transplant
April 8th 2024, 1:31am
Michael R. Migden, MD, discusses efficacy data for RP1 in advanced non-melanoma skin cancer after prior solid organ transplant.
In 5-Year Span of FDA Accelerated Approvals in Cancer, 43% Show Confirmatory Clinical Benefit
April 7th 2024, 11:37pm
Fifty-seven percent of drugs granted accelerated approval for a cancer indication failed to show clinical benefit in confirmatory studies.
Personalized Cancer Vaccine Leads to Delays in Pancreatic Cancer Recurrence
April 7th 2024, 10:11pm
Adjuvant treatment with the personalized neoantigen vaccine, autogene cevumeran, delayed pancreatic cancer recurrence in pancreatic ductal adenocarcinoma.
Cadonilimab Plus Oxaliplatin and Capecitabine Offers Survival Benefit in Gastric/GEJ Cancer
April 7th 2024, 9:45pm
Cadonilimab plus oxaliplatin and capecitabine leads to survival benefit in gastric/GEJ adenocarcinoma, regardless of PD-L1 expression.
Revumenib Demonstrates Activity in Pediatric Patients With KMT2A+ Acute Leukemia
April 4th 2024, 8:35pm
Phase 2 data from the AUGMENT-101 study show that revumenib elicits responses with acceptable safety in pediatric patients with KMT2A+ acute leukemia.
Neoadjuvant and Adjuvant Trials Could Continue to Individualize Treatment in MIBC
April 4th 2024, 5:48pm
Bernard H. Bochner, MD, FACS, discusses updates in the treatment of muscle-invasive bladder cancer and ongoing trials in the space.
Metastasis-Directed Radiotherapy Represents Significant Advancement in Prostate Cancer
April 4th 2024, 1:00pm
Daniel Spratt, MD, discusses how evolving radiation therapy techniques in prostate cancer can reduce adverse effects and shorten treatment courses.